Response to levodopa challenge in Tourette syndrome.
Identifieur interne : 000390 ( Ncbi/Curation ); précédent : 000389; suivant : 000391Response to levodopa challenge in Tourette syndrome.
Auteurs : K J Black [États-Unis] ; J W MinkSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2000.
English descriptors
- KwdEn :
- Adult, Carbidopa (administration & dosage), Carbidopa (adverse effects), Carbidopa (blood), Dopamine (blood), Dopamine (metabolism), Dopamine Agents (administration & dosage), Dopamine Agents (adverse effects), Dopamine Agents (blood), Drug Therapy, Combination, Female, Humans, Levodopa (administration & dosage), Levodopa (adverse effects), Levodopa (blood), Male, Middle Aged, Pilot Projects, Severity of Illness Index, Single-Blind Method, Tourette Syndrome (blood), Tourette Syndrome (drug therapy), Tourette Syndrome (metabolism), Treatment Outcome.
- MESH :
- chemical , administration & dosage : Carbidopa, Dopamine Agents, Levodopa.
- chemical , adverse effects : Carbidopa, Dopamine Agents, Levodopa.
- chemical , blood : Carbidopa, Dopamine, Dopamine Agents, Levodopa.
- chemical , metabolism : Dopamine.
- blood : Tourette Syndrome.
- drug therapy : Tourette Syndrome.
- metabolism : Tourette Syndrome.
- Adult, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Pilot Projects, Severity of Illness Index, Single-Blind Method, Treatment Outcome.
Abstract
A dopaminergic excess has been commonly postulated in the pathophysiology of tics, and an early report described acute worsening of tics with levodopa. However, dopamine agonists sometimes improve tics. We undertook this pilot study to determine whether people with tics could tolerate an acute dose of levodopa. Six adults with Tourette syndrome (TS) who had never been treated with neuroleptics took 150 mg levodopa by mouth under single-blind conditions after carbidopa pretreatment. All six subjects reported a decrease in self-rated tic severity (mean -40%, p <0.05), and three spontaneously asked if they could be prescribed levodopa for chronic treatment. Blinded videotape ratings of motor tic severity improved by 37% (p <0.02). A large, placebo-controlled trial will be required to confirm these findings, which raise important questions concerning the relationship of tic expression to dopaminergic activity.
PubMed: 11104204
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003E61
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :003E61
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003E85
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000390
Links to Exploration step
pubmed:11104204Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Response to levodopa challenge in Tourette syndrome.</title>
<author><name sortKey="Black, K J" sort="Black, K J" uniqKey="Black K" first="K J" last="Black">K J Black</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri</wicri:regionArea>
<placeName><region type="state">Missouri (État)</region>
<settlement type="city">Saint-Louis (Missouri)</settlement>
</placeName>
<orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName>
</affiliation>
</author>
<author><name sortKey="Mink, J W" sort="Mink, J W" uniqKey="Mink J" first="J W" last="Mink">J W Mink</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2000">2000</date>
<idno type="RBID">pubmed:11104204</idno>
<idno type="pmid">11104204</idno>
<idno type="wicri:Area/PubMed/Corpus">003E61</idno>
<idno type="wicri:Area/PubMed/Curation">003E61</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003E85</idno>
<idno type="wicri:Area/Ncbi/Merge">000390</idno>
<idno type="wicri:Area/Ncbi/Curation">000390</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Response to levodopa challenge in Tourette syndrome.</title>
<author><name sortKey="Black, K J" sort="Black, K J" uniqKey="Black K" first="K J" last="Black">K J Black</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri</wicri:regionArea>
<placeName><region type="state">Missouri (État)</region>
<settlement type="city">Saint-Louis (Missouri)</settlement>
</placeName>
<orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName>
</affiliation>
</author>
<author><name sortKey="Mink, J W" sort="Mink, J W" uniqKey="Mink J" first="J W" last="Mink">J W Mink</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2000" type="published">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Carbidopa (administration & dosage)</term>
<term>Carbidopa (adverse effects)</term>
<term>Carbidopa (blood)</term>
<term>Dopamine (blood)</term>
<term>Dopamine (metabolism)</term>
<term>Dopamine Agents (administration & dosage)</term>
<term>Dopamine Agents (adverse effects)</term>
<term>Dopamine Agents (blood)</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Levodopa (administration & dosage)</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (blood)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pilot Projects</term>
<term>Severity of Illness Index</term>
<term>Single-Blind Method</term>
<term>Tourette Syndrome (blood)</term>
<term>Tourette Syndrome (drug therapy)</term>
<term>Tourette Syndrome (metabolism)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Carbidopa</term>
<term>Dopamine Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Carbidopa</term>
<term>Dopamine Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Carbidopa</term>
<term>Dopamine</term>
<term>Dopamine Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Tourette Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Tourette Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Tourette Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pilot Projects</term>
<term>Severity of Illness Index</term>
<term>Single-Blind Method</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A dopaminergic excess has been commonly postulated in the pathophysiology of tics, and an early report described acute worsening of tics with levodopa. However, dopamine agonists sometimes improve tics. We undertook this pilot study to determine whether people with tics could tolerate an acute dose of levodopa. Six adults with Tourette syndrome (TS) who had never been treated with neuroleptics took 150 mg levodopa by mouth under single-blind conditions after carbidopa pretreatment. All six subjects reported a decrease in self-rated tic severity (mean -40%, p <0.05), and three spontaneously asked if they could be prescribed levodopa for chronic treatment. Blinded videotape ratings of motor tic severity improved by 37% (p <0.02). A large, placebo-controlled trial will be required to confirm these findings, which raise important questions concerning the relationship of tic expression to dopaminergic activity.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000390 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000390 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Ncbi |étape= Curation |type= RBID |clé= pubmed:11104204 |texte= Response to levodopa challenge in Tourette syndrome. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:11104204" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
This area was generated with Dilib version V0.6.23. |